These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34202615)

  • 1. Global Proteomic Profiling of Pediatric AML: A Pilot Study.
    Nguyen NHK; Wu H; Tan H; Peng J; Rubnitz JE; Cao X; Pounds S; Lamba JK
    Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34202615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptome Profiling of Pediatric Core Binding Factor AML.
    Hsu CH; Nguyen C; Yan C; Ries RE; Chen QR; Hu Y; Ostronoff F; Stirewalt DL; Komatsoulis G; Levy S; Meerzaman D; Meshinchi S
    PLoS One; 2015; 10(9):e0138782. PubMed ID: 26397705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?
    Dombret H; Preudhomme C; Boissel N
    Curr Opin Hematol; 2009 Mar; 16(2):92-7. PubMed ID: 19468270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia.
    Wang B; Zhang J; Hua X; Li H; Wang Z; Yang B
    Sci Rep; 2020 Jan; 10(1):685. PubMed ID: 31959790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Core binding factor acute myeloid leukaemia and c-KIT mutations.
    Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
    Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology.
    Marcucci G; Caligiuri MA; Bloomfield CD
    Cancer Invest; 2000; 18(8):768-80. PubMed ID: 11107447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
    Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
    Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia].
    Ishikawa Y
    Rinsho Ketsueki; 2018; 59(10):1997-2006. PubMed ID: 30305502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
    Marcucci G; Mrózek K; Ruppert AS; Maharry K; Kolitz JE; Moore JO; Mayer RJ; Pettenati MJ; Powell BL; Edwards CG; Sterling LJ; Vardiman JW; Schiffer CA; Carroll AJ; Larson RA; Bloomfield CD
    J Clin Oncol; 2005 Aug; 23(24):5705-17. PubMed ID: 16110030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic Profiling Identifies Specific Leukemic Stem Cell-Associated Protein Expression Patterns in Pediatric AML Patients.
    Petersen MA; Rosenberg CA; Bill M; Enemark MB; Rahbek O; Roug AS; Hasle H; Honoré B; Ludvigsen M
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications.
    Balkhi MY; Trivedi AK; Geletu M; Christopeit M; Bohlander SK; Behre HM; Behre G
    Oncogene; 2006 Nov; 25(53):7041-58. PubMed ID: 16732326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?
    Paschka P; Döhner K
    Hematology Am Soc Hematol Educ Program; 2013; 2013():209-19. PubMed ID: 24319183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?
    Marcucci G; Caligiuri MA; Bloomfield CD
    Eur J Haematol; 2003 Sep; 71(3):143-54. PubMed ID: 12930314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).
    Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; von Neuhoff C; Sander A; Schrauder A; Teigler-Schlegel A; Stary J; Corbacioglu S; Reinhardt D
    Blood; 2011 Nov; 118(20):5409-15. PubMed ID: 21948298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
    Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
    Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
    Zhu KW; Chen P; Zhang DY; Yan H; Liu H; Cen LN; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Chen XP
    J Transl Med; 2018 Apr; 16(1):90. PubMed ID: 29631596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities.
    Khalidi HS; Medeiros LJ; Chang KL; Brynes RK; Slovak ML; Arber DA
    Am J Clin Pathol; 1998 Feb; 109(2):211-20. PubMed ID: 9583894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical detection of quantitative protein biomarkers provides insights into signaling networks deregulated in acute myeloid leukemia.
    Elo LL; Karjalainen R; Ohman T; Hintsanen P; Nyman TA; Heckman CA; Aittokallio T
    Proteomics; 2014 Nov; 14(21-22):2443-53. PubMed ID: 25211154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.